)]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 382 0 obj <>>>/Resources 385 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
What other information should I know?
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 383 0 obj <>>>/Resources 387 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 387 0 obj <> endobj 388 0 obj <> endobj 386 0 obj <>stream /This label may not be the latest approved by FDA.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Polo | 100mg | 60 + 4 Pills | 189.39€ 180.37€ | |
| Viagra Generic | 150mg | 90 + 6 Pills | 147.18€ 140.17€ | |
| Viagra Generic | 150mg | 30 + 2 Pills | 72.32€ 68.88€ | |
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ | |
| Viagra Generic | 25mg | 90 + 6 Pills | 105.03€ 100.03€ | |
| Kamagra Soft Tabs | 100mg | 180 + 8 Pills | 425.45€ 405.19€ | |
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Viagra Generic | 100mg | 120 + 6 Pills | 149.50€ 142.38€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Viagra Generic | 25mg | 10 Pills | 25.19€ 23.99€ | |
| Kamagra Soft Tabs | 100mg | 272 + 12 Pills | 593.42€ 565.16€ |
For current labeling information, please visit endstream endobj 385 0 obj <> endobj 389 0 obj <> endobj 384 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 381 0 obj <> endobj 376 0 obj <>stream q 1 0 0 1 -8.535767 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.535767 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.4642 47.6228 Tm ( )Tj 19.25 -0.005 Td (8)Tj 0.0009 Tc -0.0009 Tw -19.25 54.94 Td [(on placebo.
what is Fildena 150 prescribed for?
Apcalis SX Jelly
In the titration studies \(n=644\) \(with m)8.7 (o)0.9 (st patients eventually receiving 100 m)8.7 (g)0.9 (\), )]TJ 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(results were sim)8.9 (ilar. )]TJ 0 Tc 0 Tw -0.3 -1.165 Td ( )Tj 0.3 -17.655 Td ( )Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 205.8 524.58 22.86 33.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 205.26 524.58 24 33.78 re W n 0.961 w 1 j 1 J 205.8 557.82 22.86 -33.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 262.5 524.58 22.86 87.12 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 261.96 524.58 24 87.66 re W n 0.961 w 1 j 1 J 262.5 611.7 22.86 -87.12 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 319.2 524.58 22.62 102.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 318.66 524.58 23.76 102.78 re W n 0.961 w 1 j 1 J 319.2 626.82 22.62 -102.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 375.66 524.58 22.86 113.34 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 375.12 524.58 24 113.88 re W n 0.961 w 1 j 1 J 375.66 637.92 22.86 -113.34 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 0.06 w 1 j 1 J q 1 0 0 1 189 662.88 cm 0 0 m 0 -138.3 l -2.4 -138.3 m 2.4 -138.3 l -2.4 -110.64 m 2.4 -110.64 l -2.4 -82.98 m 2.4 -82.98 l -2.4 -55.32 m 2.4 -55.32 l -2.4 -27.66 m 2.4 -27.66 l -2.4 0 m 2.4 0 l 0 -138.3 m 226.56 -138.3 l 0 -140.7 m 0 -135.84 l 56.7 -140.7 m 56.7 -135.84 l 113.4 -140.7 m 113.4 -135.84 l 169.86 -140.7 m 169.86 -135.84 l 226.56 -140.7 m 226.56 -135.84 l S Q Q BT /TT1 1 Tf 7.9369 0 0 7.9369 170.1442 520.4828 Tm (0)Tj -0.0119 Tc -0.544 3.485 Td (20)Tj 0 3.485 TD (40)Tj T* (60)Tj T* (80)Tj -0.544 3.485 Td (100)Tj -0.0421 Tc 4.233 -18.884 Td [(P)-40.4 (l)-31.6 (ac)-63.7 (eb)-30.2 (o)]TJ -0.0107 Tc 0.363 -1.3 Td [(n=4)-6.4 (6)1.2 (3)]TJ -0.0027 Tc 6.63 1.3 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (25 mg)Tj 0 Tw -0.03 -1.308 Td [(n=2)-6.4 (1)1.2 (4)]TJ -0.0027 Tc 6.6 2.608 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (50 mg)Tj 0 Tw -0.03 -1.308 Td [(n=3)-6.4 (9)1.2 (1)]TJ -0.0027 Tc 6.63 2.608 Td [(VIAG)-11.1 (R)-13.8 (A)]TJ -0.0109 Tc 0.0052 Tw 0.272 -1.3 Td (100 mg)Tj -0.0107 Tc 0 Tw 0.242 -1.308 Td [(n=3)-6.4 (8)1.2 (0)]TJ -0.0421 Tc 0.0364 Tw -12.927 -1.724 Td [(T)-73.8 (r)-41.7 (eat)-36.4 (m)-25.5 (en)-30.2 (t)-36.4 ( g)-30.2 (r)-41.7 (ou)-30.2 (p)]TJ 0.0019 Tc 0 Tw 0 7.9369 -7.9369 0 155.5642 518.3828 Tm [(Percentage pati)4.8 (ents reporti)4.8 (ng i)4.8 (m)3.3 (proveme)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 156.78 520.2 9.18 148.26 re W n 1 0 0 1 8.535767 1.877228 cm BT 0 Tc 0 7.9369 -7.9369 0 155.5642 664.4228 Tm (n)Tj ET Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 209.4 559.98 28.86 13.68 re f Q BT -0.0119 Tc 7.9369 0 0 7.9369 203.0242 563.5028 Tm [(24)-7.6 (%)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 377.82 638.64 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 371.4442 642.6428 Tm (82%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 322.56 627.54 21.9 14.22 re f Q BT 7.9369 0 0 7.9369 316.1842 631.6028 Tm (74%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 266.34 613.14 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 259.9642 617.1428 Tm [(63)-7.6 (%)]TJ /TT0 1 Tf 0 Tc 12 0 0 12 470.2042 467.0228 Tm ( )Tj 0.0011 Tc 0.0022 Tw 9 0 0 9 63.4642 458.6228 Tm ( )Tj 9 0 Td (Overall treatment p<0.0001 )Tj 0 Tc 0 Tw 12 0 0 12 63.4642 445.1828 Tm ( )Tj 0.0008 Tc 0.0006 Tw 10.98 0 0 10.98 203.9242 432.2228 Tm (Figure 4.
- Sildenafil citrate tablets are used to treat erectile dysfunction.
- The typical dosage of sildenafil citrate is 150 mg.
- These tablets work by increasing blood flow to the penis.
- Consult a doctor before taking 150 mg sildenafil tablets.
Percentage of Patients Reporting )Tj 0.0011 Tc 0.0003 Tw 2.568 -1.159 Td [(an Im)8.4 (provem)8.4 (e)2.3 (nt in Erections. )]TJ 0 Tc 0 Tw 12 0 0 12 59.8642 405.7628 Tm ( )Tj 0.0006 Tc -0.0006 Tw 0.3 -1.165 Td (The patients in studies had varying degrees of ED. One-third to one-half\ of the subjects in these )Tj 0.0009 Tc -0.0009 Tw 0 sildenafil 100g -1.165 TD [(studies reported successful intercourse at leas)-2.2 (t once during a 4-week, treatm)8.7 (ent-free run-in )]TJ 0.0007 Tc 0 Tw T* (period. )Tj 0 Tc -0.3 -1.165 Td ( )Tj 0.0007 Tc -0.0007 Tw 0.3 -1.165 Td [(In m)8.5 (any of)3.7 ( the studies, of)3.7 ( both f)3.7 (i)-1.5 (xed dose and titration designs, daily diaries were kept by )]TJ 0.0008 Tc -0.0008 Tw T* (patients.
- Following a healthy lifestyle can improve treatment outcomes.
- It’s important to confirm a diagnosis before starting sildenafil.
- Side effect severity can depend on dosage and individual factors.
- A doctor may adjust doses based on patient response.
In these studies, involving about 1600 patie)Tj 0.0006 Tc -0.0006 Tw 21.065 0 Td (nts, analyses of patient diaries showed no )Tj 0.0003 Tc -0.0003 Tw -21.065 -1.165 Td [(effect of VIAGRA on rates of attem)8.1 (pted interc)]TJ 0.0008 Tc -0.0008 Tw 18.69 0 Td (ourse \(about 2 per week\), but there was clear )Tj 0.0009 Tc -0.0009 Tw -18.69 -1.165 Td [(treatm)8.7 (ent-related im)8.7 (provem)8.7 (ent in sexual function: per patient weekly success rates averaged 1.3 )]TJ 0 Tc 0 Tw T* [(on 50-100 m)7.8 (g of VIAGRA vs 0.4 on placebo; si)]TJ 0.001 Tc -0.001 Tw 19.27 0 Td [(m)8.8 (ilarly, group m)8.8 (ean success rates \(total )]TJ 0.0006 Tc -0.0006 Tw -19.27 -1.165 Td [(successes divided by total attem)8.4 (p)0.6 (ts\) were about 66% on VIAGRA vs about 20% on placebo.
- The medication may interact with antibiotics like erythromycin.
- Patients with eye disorders should consult their doctor before use.
- Sildenafil citrate tablets are often used recreationally as well.
- Overuse or misuse can lead to health complications.
)]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(During 3 to 6 m)8.3 (onths of double-blind treatm)8.3 (e)-0.7 (nt or)]TJ 0.0008 Tc -0.0008 Tw 20.12 0 Td [( longer-term)8.6 ( \(1 year\), open-label studies, few )]TJ -20.12 -1.165 Td [(patients withdrew from)8.6 ( active treatm)8.6 (ent for any )]TJ 0.0005 Tc -0.0005 Tw 19.37 0 Td (reason, including lack of effectiveness.
| Parameter | Value | Description |
|---|---|---|
| Absorption | Peak in 30-120 minutes | Time to reach maximum plasma concentration |
| Bioavailability | Approx. 40% | Percentage of dose absorbed into circulation |
| Distribution | Wide tissue distribution | Binds to plasma proteins |
| Metabolism | Liver via CYP3A4 | Main metabolic pathway |
| Excretion | Mainly in feces and urine | Elimination route |
At the )Tj 0.0007 Tc -0.0007 Tw -19.37 -1.165 Td [(end of the long-term)8.5 ( study, 88% of patients re)2.2 (ported that VIAGRA im)8.4 (proved their erections.
What precautions need to take before using Fildena extra power 150 mg?
In these studies, involving about 1600 patie)Tj 0.0006 Tc -0.0006 Tw 21.065 0 Td (nts, analyses of patient diaries showed no )Tj 0.0003 Tc -0.0003 Tw -21.065 -1.165 Td [(effect of VIAGRA on rates of attem)8.1 (pted interc)]TJ 0.0008 Tc -0.0008 Tw 18.69 0 Td (ourse \(about 2 per week\), but there was clear )Tj 0.0009 Tc -0.0009 Tw -18.69 -1.165 Td [(treatm)8.7 (ent-related im)8.7 (provem)8.7 (ent in sexual function: per patient weekly success rates averaged 1.3 )]TJ 0 Tc 0 Tw T* [(on 50-100 m)7.8 (g of VIAGRA vs 0.4 on placebo; si)]TJ 0.001 Tc -0.001 Tw 19.27 0 Td [(m)8.8 (ilarly, group m)8.8 (ean success rates \(total )]TJ 0.0006 Tc -0.0006 Tw -19.27 -1.165 Td [(successes divided by total attem)8.4 (p)0.6 (ts\) were about 66% on VIAGRA vs about 20% on placebo. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(During 3 to 6 m)8.3 (onths of double-blind treatm)8.3 (e)-0.7 (nt or)]TJ 0.0008 Tc -0.0008 Tw 20.12 0 Td [( longer-term)8.6 ( \(1 year\), open-label studies, few )]TJ -20.12 -1.165 Td [(patients withdrew from)8.6 ( active treatm)8.6 (ent for any )]TJ 0.0005 Tc -0.0005 Tw 19.37 0 Td (reason, including lack of effectiveness. At the )Tj 0.0007 Tc -0.0007 Tw -19.37 -1.165 Td [(end of the long-term)8.5 ( study, 88% of patients re)2.2 (ported that VIAGRA im)8.4 (proved their erections. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* (Men with untreated ED had relatively low baseline scores for all aspects\ of sexual function )Tj T* [(m)8.4 (easured \(again using a 5-point scale\) in the IIEF. VIAGRA im)8.4 (proved these aspects of sexual )]TJ 0.0005 Tc -0.0005 Tw T* [(function: frequency, firm)8.3 (ness and m)8.3 (a)-0.7 (intenance of )]TJ 0.0006 Tc -0.0006 Tw 20.135 0 Td [(erections; frequency of orgasm)8.4 (; frequency and )]TJ 0.0009 Tc -0.0009 Tw -20.135 -1.165 Td [(level of desire; frequency, satisfaction and enjoym)8.7 (ent of intercourse; and overall relationship )]TJ 0.0008 Tc 0 Tw T* (satisfaction.
What should I know about sildenafil before taking it?
)Tj 0 Tc T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(One random)8.4 (ized, double-blind, flexible-dose, )]TJ 0.0009 Tc -0.0009 Tw (placebo-controlled study included only patients )Tj 0.0008 Tc -0.0008 Tw T* [(with erectile dysfunction attributed to com)8.6 (p)0.8 (lications of diabetes m)8.6 (ellitus \(n=268\). As in the other )]TJ T* [(titration studies, patients were started on 50 m)8.6 (g)0.8 ( and allowed to adjust the dose up to 100 m)8.6 (g)0.8 ( or )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 378 0 obj <>>>/Resources 391 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 379 0 obj <>>>/Resources 393 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 393 0 obj <> endobj 394 0 obj <> endobj 392 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 391 0 obj <> endobj 395 0 obj <> endobj 390 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 377 0 obj <> endobj 372 0 obj <>stream q 1 0 0 1 -7.90155 3.480774 cm 0 0 612 792 re W n 1 0 0 1 7.90155 -3.480774 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 64.0985 52.9808 Tm ( )Tj 19.25 -0.005 Td (7)Tj -19.25 36.755 Td ( )Tj ET q 1 0 0 1 -7.90155 3.480774 cm 1 g 182.82 532.44 256.44 127.38 re f Q q 1 0 0 1 -7.90155 3.480774 cm 1 G 0.959 w 1 j 1 J q 1 0 0 1 182.82 659.82 cm 0 0 m 256.44 0 l 256.44 0 m 256.44 -127.38 l 256.44 -127.38 m 0 -127.38 l 0 -127.38 m 0 0 l S Q Q q 1 0 0 1 -7.90155 3.480774 cm 186.48 532.44 6.9 40.5 re W n 1 g 187.02 532.44 5.76 39.96 re f 0.959 w 1 j 1 J 187.02 572.4 5.76 -39.96 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 229.68 532.44 5.76 11.76 re f Q q 1 0 0 1 -7.90155 3.480774 cm 229.14 532.44 6.9 12.3 re W n 0.959 w 1 j 1 J 229.68 544.2 5.76 -11.76 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 272.52 532.44 5.76 3.24 re f Q q 1 0 0 1 -7.90155 3.480774 cm 271.98 532.44 6.9 3.78 re W n 0.959 w 1 j 1 J 272.52 535.68 5.76 -3.24 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 315.24 532.44 5.76 2.28 re f Q q 1 0 0 1 -7.90155 3.480774 cm 314.7 532.44 6.9 2.82 re W n 0.959 w 1 j 1 J 315.24 534.72 5.76 -2.28 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 357.96 532.44 5.76 1.56 re f Q q 1 0 0 1 -7.90155 3.480774 cm 357.42 532.44 6.9 2.1 re W n 0.959 w 1 j 1 J 357.96 534 5.76 -1.56 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 192.78 532.44 5.64 31.32 re f Q q 1 0 0 1 -7.90155 3.480774 cm 192.24 532.44 6.78 31.86 re W n 0.959 w 1 j 1 J 192.78 563.76 5.64 -31.32 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 235.44 532.44 5.64 40.44 re f Q q 1 0 0 1 -7.90155 3.480774 cm 234.9 532.44 6.78 40.98 re W n 0.959 w 1 j 1 J 235.44 572.88 5.64 -40.44 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 278.28 532.44 5.64 8.88 re f Q q 1 0 0 1 -7.90155 3.480774 cm 277.74 532.44 6.78 9.42 re W n 0.959 w 1 j 1 J 278.28 541.32 5.64 -8.88 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 321 532.44 5.64 3.36 re f Q q 1 0 0 1 -7.90155 3.480774 cm 320.46 532.44 6.78 3.9 re W n 0.959 w 1 j 1 J 321 535.8 5.64 -3.36 re S Q q 1 0 0 1 -7.90155 3.480774 cm 198.42 532.44 5.76 15.6 re f Q q 1 0 0 1 -7.90155 3.480774 cm 197.88 532.44 6.9 16.14 re W n 0.959 w 1 j 1 J 198.42 548.04 5.76 -15.6 re S Q q 1 0 0 1 -7.90155 3.480774 cm 241.08 532.44 5.76 18.12 re f Q q 1 0 0 1 -7.90155 3.480774 cm 240.54 532.44 6.9 18.66 re W n 0.959 w 1 j 1 J 241.08 550.56 5.76 -18.12 re S Q q 1 0 0 1 -7.90155 3.480774 cm 283.92 532.44 5.76 17.88 re f Q q 1 0 0 1 -7.90155 3.480774 cm 283.38 532.44 6.9 18.42 re W n 0.959 w 1 j 1 J 283.92 550.32 5.76 -17.88 re S Q q 1 0 0 1 -7.90155 3.480774 cm 326.64 532.44 5.76 13.32 re f Q q 1 0 0 1 -7.90155 3.480774 cm 326.1 532.44 6.9 13.86 re W n 0.959 w 1 j 1 J 326.64 545.76 5.76 -13.32 re S Q q 1 0 0 1 -7.90155 3.480774 cm 369.36 532.44 5.76 7.8 re f Q q 1 0 0 1 -7.90155 3.480774 cm 368.82 532.44 6.9 8.34 re W n 0.959 w 1 j 1 J 369.36 540.24 5.76 -7.8 re S Q q 1 0 0 1 -7.90155 3.480774 cm 412.14 532.44 5.76 6.36 re f Q q 1 0 0 1 -7.90155 3.480774 cm 411.6 532.44 6.9 6.9 re W n 0.959 w 1 j 1 J 412.14 538.8 5.76 -6.36 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 204.18 532.44 5.64 9.72 re f Q q 1 0 0 1 -7.90155 3.480774 cm 203.64 532.44 6.78 10.26 re W n 0.959 w 1 j 1 J 204.18 542.16 5.64 -9.72 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 246.84 532.44 5.76 13.8 re f Q q 1 0 0 1 -7.90155 3.480774 cm 246.3 532.44 6.9 14.34 re W n 0.959 w 1 j 1 J 246.84 546.24 5.76 -13.8 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 289.68 532.44 5.64 18.48 re f Q q 1 0 0 1 -7.90155 3.480774 cm 289.14 532.44 6.78 19.02 re W n 0.959 w 1 j 1 J 289.68 550.92 5.64 -18.48 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 332.4 532.44 5.64 14.52 re f Q q 1 0 0 1 -7.90155 3.480774 cm 331.86 532.44 6.78 15.06 re W n 0.959 )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* (Men with untreated ED had relatively low baseline scores for all aspects\ of sexual function )Tj T* [(m)8.4 (easured \(again using a 5-point scale\) in the IIEF.
What happens if I overdose?
)]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj T* ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 382 0 obj <>>>/Resources 385 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 383 0 obj <>>>/Resources 387 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 387 0 obj <> endobj 388 0 obj <> endobj 386 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 385 0 obj <> endobj 389 0 obj <> endobj 384 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 381 0 obj <> endobj 376 0 obj <>stream q 1 0 0 1 -8.535767 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.535767 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.4642 47.6228 Tm ( )Tj 19.25 -0.005 Td (8)Tj 0.0009 Tc -0.0009 Tw -19.25 54.94 Td [(on placebo. In the titration studies \(n=644\) \(with m)8.7 (o)0.9 (st patients eventually receiving 100 m)8.7 (g)0.9 (\), )]TJ 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(results were sim)8.9 (ilar.
Erectile Dysfunction
)]TJ 0 Tc 0 Tw -0.3 -1.165 Td ( )Tj 0.3 -17.655 Td ( )Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 205.8 524.58 22.86 33.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 205.26 524.58 24 33.78 re W n 0.961 w 1 j 1 J 205.8 557.82 22.86 -33.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 262.5 524.58 22.86 87.12 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 261.96 524.58 24 87.66 re W n 0.961 w 1 j 1 J 262.5 611.7 22.86 -87.12 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 319.2 524.58 22.62 102.24 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 318.66 524.58 23.76 102.78 re W n 0.961 w 1 j 1 J 319.2 626.82 22.62 -102.24 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 375.66 524.58 22.86 113.34 re f Q q 1 0 0 1 -8.535767 -1.877228 cm 375.12 524.58 24 113.88 re W n 0.961 w 1 j 1 J 375.66 637.92 22.86 -113.34 re S Q q 1 0 0 1 -8.535767 -1.877228 cm 0.06 w 1 j 1 J q 1 0 0 1 189 662.88 cm 0 0 m 0 -138.3 l -2.4 -138.3 m 2.4 -138.3 l -2.4 -110.64 m 2.4 -110.64 l -2.4 -82.98 m 2.4 -82.98 l -2.4 -55.32 m 2.4 -55.32 l -2.4 -27.66 m 2.4 -27.66 l -2.4 0 m 2.4 0 l 0 -138.3 m 226.56 -138.3 l 0 -140.7 m 0 -135.84 l 56.7 -140.7 m 56.7 -135.84 l 113.4 -140.7 m 113.4 -135.84 l 169.86 -140.7 m 169.86 -135.84 l 226.56 -140.7 m 226.56 -135.84 l S Q Q BT /TT1 1 Tf 7.9369 0 0 7.9369 170.1442 520.4828 Tm (0)Tj -0.0119 Tc -0.544 3.485 Td (20)Tj 0 3.485 TD (40)Tj T* (60)Tj T* (80)Tj -0.544 3.485 Td (100)Tj -0.0421 Tc 4.233 -18.884 Td [(P)-40.4 (l)-31.6 (ac)-63.7 (eb)-30.2 (o)]TJ -0.0107 Tc 0.363 -1.3 Td [(n=4)-6.4 (6)1.2 (3)]TJ -0.0027 Tc 6.63 1.3 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (25 mg)Tj 0 Tw -0.03 -1.308 Td [(n=2)-6.4 (1)1.2 (4)]TJ -0.0027 Tc 6.6 2.608 Td [(VIAG)-18.6 (R)-6.3 (A)]TJ -0.0107 Tc 0.005 Tw 0.544 -1.3 Td (50 mg)Tj 0 Tw -0.03 -1.308 Td [(n=3)-6.4 (9)1.2 (1)]TJ -0.0027 Tc 6.63 2.608 Td [(VIAG)-11.1 (R)-13.8 (A)]TJ -0.0109 Tc 0.0052 Tw 0.272 -1.3 Td (100 mg)Tj -0.0107 Tc 0 Tw 0.242 -1.308 Td [(n=3)-6.4 (8)1.2 (0)]TJ -0.0421 Tc 0.0364 Tw -12.927 -1.724 Td [(T)-73.8 (r)-41.7 (eat)-36.4 (m)-25.5 (en)-30.2 (t)-36.4 ( g)-30.2 (r)-41.7 (ou)-30.2 (p)]TJ 0.0019 Tc 0 Tw 0 7.9369 -7.9369 0 155.5642 518.3828 Tm [(Percentage pati)4.8 (ents reporti)4.8 (ng i)4.8 (m)3.3 (proveme)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 156.78 520.2 9.18 148.26 re W n 1 0 0 1 8.535767 1.877228 cm BT 0 Tc 0 7.9369 -7.9369 0 155.5642 664.4228 Tm (n)Tj ET Q q 1 0 0 1 -8.535767 -1.877228 cm 1 g 209.4 559.98 28.86 13.68 re f Q BT -0.0119 Tc 7.9369 0 0 7.9369 203.0242 563.5028 Tm [(24)-7.6 (%)]TJ ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 377.82 638.64 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 371.4442 642.6428 Tm (82%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 322.56 627.54 21.9 14.22 re f Q BT 7.9369 0 0 7.9369 316.1842 631.6028 Tm (74%)Tj ET q 1 0 0 1 -8.535767 -1.877228 cm 1 g 266.34 613.14 21.9 14.16 re f Q BT 7.9369 0 0 7.9369 259.9642 617.1428 Tm [(63)-7.6 (%)]TJ /TT0 1 Tf 0 Tc 12 0 0 12 470.2042 467.0228 Tm ( )Tj 0.0011 Tc 0.0022 Tw 9 0 0 9 63.4642 458.6228 Tm ( )Tj 9 0 Td (Overall treatment p<0.0001 )Tj 0 Tc 0 Tw 12 0 0 12 63.4642 445.1828 Tm ( )Tj 0.0008 Tc 0.0006 Tw 10.98 0 0 10.98 203.9242 432.2228 Tm (Figure 4. Percentage of Patients Reporting )Tj 0.0011 Tc 0.0003 Tw 2.568 -1.159 Td [(an Im)8.4 (provem)8.4 (e)2.3 (nt in Erections. )]TJ 0 Tc 0 Tw 12 0 0 12 59.8642 405.7628 Tm ( )Tj 0.0006 Tc -0.0006 Tw 0.3 -1.165 Td (The patients in studies had varying degrees of ED. One-third to one-half\ of the subjects in these )Tj 0.0009 Tc -0.0009 Tw 0 sildenafil 100g -1.165 TD [(studies reported successful intercourse at leas)-2.2 (t once during a 4-week, treatm)8.7 (ent-free run-in )]TJ 0.0007 Tc 0 Tw T* (period. )Tj 0 Tc -0.3 -1.165 Td ( )Tj 0.0007 Tc -0.0007 Tw 0.3 -1.165 Td [(In m)8.5 (any of)3.7 ( the studies, of)3.7 ( both f)3.7 (i)-1.5 (xed dose and titration designs, daily diaries were kept by )]TJ 0.0008 Tc -0.0008 Tw T* (patients. VIAGRA im)8.4 (proved these aspects of sexual )]TJ 0.0005 Tc -0.0005 Tw T* [(function: frequency, firm)8.3 (ness and m)8.3 (a)-0.7 (intenance of )]TJ 0.0006 Tc -0.0006 Tw 20.135 0 Td [(erections; frequency of orgasm)8.4 (; frequency and )]TJ 0.0009 Tc -0.0009 Tw -20.135 -1.165 Td [(level of desire; frequency, satisfaction and enjoym)8.7 (ent of intercourse; and overall relationship )]TJ 0.0008 Tc 0 Tw T* (satisfaction. )Tj 0 Tc T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(One random)8.4 (ized, double-blind, flexible-dose, )]TJ 0.0009 Tc -0.0009 Tw (placebo-controlled study included only patients )Tj 0.0008 Tc -0.0008 Tw T* [(with erectile dysfunction attributed to com)8.6 (p)0.8 (lications of diabetes m)8.6 (ellitus \(n=268\).
| Side Effect | Frequency | Severity | Notes |
|---|---|---|---|
| Headache | Very common | Mild to moderate | Usually transient |
| Flushing | Common | Mild | Due to vasodilation |
| Dyspepsia | Common | Mild | Indigestion |
| Nasal Congestion | Less common | Mild | Sinus tissues affected |
As in the other )]TJ T* [(titration studies, patients were started on 50 m)8.6 (g)0.8 ( and allowed to adjust the dose up to 100 m)8.6 (g)0.8 ( or )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 378 0 obj <>>>/Resources 391 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
Further information
Customers say
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 379 0 obj <>>>/Resources 393 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 393 0 obj <> endobj 394 0 obj <> endobj 392 0 obj <>stream /This label may not be the latest approved by FDA.
In case of emergency/overdose
Dosage adjustments
For current labeling information, please visit endstream endobj 391 0 obj <> endobj 395 0 obj <> endobj 390 0 obj <>stream /This label may not be the latest approved by FDA.
| Condition | Description | Recommended Dosage |
|---|---|---|
| Erectile Dysfunction | Difficulty achieving or maintaining erection | 150 mg as needed |
| Pulmonary Arterial Hypertension | Used to relax blood vessels in lungs | As prescribed by doctor |
| Off-label Uses | Other experimental benefits | Not specified |
For current labeling information, please visit endstream endobj 377 0 obj <> endobj 372 0 obj <>stream q 1 0 0 1 -7.90155 3.480774 cm 0 0 612 792 re W n 1 0 0 1 7.90155 -3.480774 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 64.0985 52.9808 Tm ( )Tj 19.25 -0.005 Td (7)Tj -19.25 36.755 Td ( )Tj ET q 1 0 0 1 -7.90155 3.480774 cm 1 g 182.82 532.44 256.44 127.38 re f Q q 1 0 0 1 -7.90155 3.480774 cm 1 G 0.959 w 1 j 1 J q 1 0 0 1 182.82 659.82 cm 0 0 m 256.44 0 l 256.44 0 m 256.44 -127.38 l 256.44 -127.38 m 0 -127.38 l 0 -127.38 m 0 0 l S Q Q q 1 0 0 1 -7.90155 3.480774 cm 186.48 532.44 6.9 40.5 re W n 1 g 187.02 532.44 5.76 39.96 re f 0.959 w 1 j 1 J 187.02 572.4 5.76 -39.96 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 229.68 532.44 5.76 11.76 re f Q q 1 0 0 1 -7.90155 3.480774 cm 229.14 532.44 6.9 12.3 re W n 0.959 w 1 j 1 J 229.68 544.2 5.76 -11.76 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 272.52 532.44 5.76 3.24 re f Q q 1 0 0 1 -7.90155 3.480774 cm 271.98 532.44 6.9 3.78 re W n 0.959 w 1 j 1 J 272.52 535.68 5.76 -3.24 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 315.24 532.44 5.76 2.28 re f Q q 1 0 0 1 -7.90155 3.480774 cm 314.7 532.44 6.9 2.82 re W n 0.959 w 1 j 1 J 315.24 534.72 5.76 -2.28 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 357.96 532.44 5.76 1.56 re f Q q 1 0 0 1 -7.90155 3.480774 cm 357.42 532.44 6.9 2.1 re W n 0.959 w 1 j 1 J 357.96 534 5.76 -1.56 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 192.78 532.44 5.64 31.32 re f Q q 1 0 0 1 -7.90155 3.480774 cm 192.24 532.44 6.78 31.86 re W n 0.959 w 1 j 1 J 192.78 563.76 5.64 -31.32 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 235.44 532.44 5.64 40.44 re f Q q 1 0 0 1 -7.90155 3.480774 cm 234.9 532.44 6.78 40.98 re W n 0.959 w 1 j 1 J 235.44 572.88 5.64 -40.44 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 278.28 532.44 5.64 8.88 re f Q q 1 0 0 1 -7.90155 3.480774 cm 277.74 532.44 6.78 9.42 re W n 0.959 w 1 j 1 J 278.28 541.32 5.64 -8.88 re S Q q 1 0 0 1 -7.90155 3.480774 cm 0.59 g 321 532.44 5.64 3.36 re f Q q 1 0 0 1 -7.90155 3.480774 cm 320.46 532.44 6.78 3.9 re W n 0.959 w 1 j 1 J 321 535.8 5.64 -3.36 re S Q q 1 0 0 1 -7.90155 3.480774 cm 198.42 532.44 5.76 15.6 re f Q q 1 0 0 1 -7.90155 3.480774 cm 197.88 532.44 6.9 16.14 re W n 0.959 w 1 j 1 J 198.42 548.04 5.76 -15.6 re S Q q 1 0 0 1 -7.90155 3.480774 cm 241.08 532.44 5.76 18.12 re f Q q 1 0 0 1 -7.90155 3.480774 cm 240.54 532.44 6.9 18.66 re W n 0.959 w 1 j 1 J 241.08 550.56 5.76 -18.12 re S Q q 1 0 0 1 -7.90155 3.480774 cm 283.92 532.44 5.76 17.88 re f Q q 1 0 0 1 -7.90155 3.480774 cm 283.38 532.44 6.9 18.42 re W n 0.959 w 1 j 1 J 283.92 550.32 5.76 -17.88 re S Q q 1 0 0 1 -7.90155 3.480774 cm 326.64 532.44 5.76 13.32 re f Q q 1 0 0 1 -7.90155 3.480774 cm 326.1 532.44 6.9 13.86 re W n 0.959 w 1 j 1 J 326.64 545.76 5.76 -13.32 re S Q q 1 0 0 1 -7.90155 3.480774 cm 369.36 532.44 5.76 7.8 re f Q q 1 0 0 1 -7.90155 3.480774 cm 368.82 532.44 6.9 8.34 re W n 0.959 w 1 j 1 J 369.36 540.24 5.76 -7.8 re S Q q 1 0 0 1 -7.90155 3.480774 cm 412.14 532.44 5.76 6.36 re f Q q 1 0 0 1 -7.90155 3.480774 cm 411.6 532.44 6.9 6.9 re W n 0.959 w 1 j 1 J 412.14 538.8 5.76 -6.36 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 204.18 532.44 5.64 9.72 re f Q q 1 0 0 1 -7.90155 3.480774 cm 203.64 532.44 6.78 10.26 re W n 0.959 w 1 j 1 J 204.18 542.16 5.64 -9.72 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 246.84 532.44 5.76 13.8 re f Q q 1 0 0 1 -7.90155 3.480774 cm 246.3 532.44 6.9 14.34 re W n 0.959 w 1 j 1 J 246.84 546.24 5.76 -13.8 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 289.68 532.44 5.64 18.48 re f Q q 1 0 0 1 -7.90155 3.480774 cm 289.14 532.44 6.78 19.02 re W n 0.959 w 1 j 1 J 289.68 550.92 5.64 -18.48 re S Q q 1 0 0 1 -7.90155 3.480774 cm 1 g 332.4 532.44 5.64 14.52 re f Q q 1 0 0 1 -7.90155 3.480774 cm 331.86 532.44 6.78 15.06 re W n 0.959
- Alcohol can increase the risk of side effects from sildenafil.
- Taking sildenafil does not protect against sexually transmitted infections.
- Patients should inform their doctor of all medications they take.
- Sildenafil may cause a drop in blood pressure in some cases.
- Investigating Sildenafil for Female Orgasmic Disorder
- Generic Equivalent of Viagra
- To Buy Cenforce US Visit Our Pharmacy ↓
- How to Find the Best Deals on Generic Sildenafil
- To Where To Buy Super Cialis Online Visit Our Pharmacy ↓
- Viagra Generic online Greece γενοσημο βιαγκρα τιμη στην φαρμακειου
- SILDENAFIL PFIZER